Dual GIP/GLP-1 receptor agonist for metabolic research.
Tirzepatide engages both GIP and GLP-1 receptors, of interest in metabolic and glycemic research models.
Dual incretin receptor activation enhances glucose-dependent insulin response and modulates appetite-regulating pathways.
Peptide engages target receptor with high affinity.
Downstream intracellular pathways activate.
Gene expression and protein synthesis shift.
Measurable change in the studied biomarker.
Phase 3 study of tirzepatide 5, 10, 15 mg vs. placebo on body weight in adults without diabetes.
Mean weight reductions of −15.0%, −19.5%, −20.9% across doses vs. −3.1% placebo.
Head-to-head tirzepatide vs. semaglutide 1 mg in inadequately controlled T2D.
Superior HbA1c reduction across all doses and greater weight loss vs. semaglutide.
Tirzepatide monotherapy vs. placebo as first-line pharmacotherapy.
HbA1c reductions of 1.87–2.07% with weight loss of 7.0–9.5 kg.
Refrigerate post-reconstitution at 2–8°C. Lyophilized -20°C, light-protected.
Strictly for in-vitro laboratory and research investigations.
Not approved for diagnostic, therapeutic, or veterinary application.
Handling restricted to licensed researchers and laboratory staff.
Warning — Tirzepatide is supplied solely for legitimate laboratory research. Any administration to humans or animals is strictly prohibited and may violate federal, state, or local law. By purchasing, the researcher accepts full responsibility for safe handling, storage, and lawful use.
